APOL1 and kidney disorder: The immediate question of high importance is “Should the four surrogate end points in the Rosenberg study be adopted as valid surrogate clinical trial end points by clinical trialists and the regulatory agencies in studies of APOL1-associated kidney disease?” In the judgment of this commentator, the answer to the foregoing question is a qualified yes.